TORONTO AFX - Procter & Gamble and Sanofi Aventis said a recent phase III trial on osteoporosis drug risedronate found a statistically significant 4.5 pct increase in bone density in men.
'In the trial ... patients treated with risedronate experienced statistically significant improvements in lumbar spine bone mineral density at all time points measured, 3, 6, 12, and 24 months,' the two groups said.
They added that: 'Overall, risedronate was well-tolerated, and adverse events were generally similar between patients receiving risedronate and patients receiving placebo.'
The trial was sponsored by The Alliance for Better Bone Health - a collaboration between Procter & Gamble and Sanofi-Aventis. email@example.com ma COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Kostenloser Wertpapierhandel auf Smartbroker.de